Clinical trials: Arts
HIV-1 Infection
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and eventually immune deficiency.
- Trial name
- Re-boost (NCT01712256)
- Testing
- Vacc-4x
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Bionor Immuno AS
Large B-cell Diffuse Lymphoma of Testis
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by…
- Trial name
- IELSG30 (NCT00945724)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
- Where
- 22 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
Wound of Skin
Autologous Regeneration of Tissue (ART) for Wound Healing
The purpose of this research study is to learn about a new device, Autologous Regeneration of Tissue (ART), for collecting skin grafts from participant's own skin.
- Trial name
- NCT03796988
- Testing
- Autologous Regeneration of Tissue (ART) device
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
HIV, AIDS
Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia
The specific aim of the study is to assess antiretroviral therapy adherence and evaluate the impact of a situated treatment adherence intervention program among persons living with HIV/AIDS on antiretroviral therapy in Estonia.
- Conditions
- HIV, AIDS, Medication Adherence
- Trial name
- NCT01789138
- Testing
- Situated Optimal Adherence Intervention
- Where
- 2 sites in Estonia
- Volunteers
- 519 people
- Sponsor
- University of Tartu
Veteran, Smoking Cessation
Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers
The primary goal of the current study is to evaluate the effectiveness of a combined tele-health and contingency management (CM) intervention that investigators are calling Abstinence Reinforcement Therapy (ART).
- Trial name
- NCT01723163
- Testing
- Abstinence Reinforcement Therapy (ART), Telephone Counseling and NRT
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- VA Office of Research and Development
Human Immunodeficiency Virus, Alcohol-Related Disorders
Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa
The purpose of this study is to test the effectiveness and implementation of a brief, integrated behavioral intervention for HIV medication adherence and substance use in the HIV care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use
- Trial name
- NCT03529409
- Testing
- Project Khanya
- Where
- 2 sites in United States, South Africa
- Volunteers
- 66 people
- Sponsor
- University of Maryland, College Park
Infection, Human Immunodeficiency Virus I, HIV Infection
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.
- Trial name
- ASSERT (NCT00549198)
- Testing
- Abacavir/lamivudine and efavirenz, Tenofovir/Emtricitabine and efavirenz
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 392 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease
The purpose of this study is to test the safety and efficacy of using of a portable exoskeleton for walking training in persons with Parkinson's disease that have gait mobility problems and/or postural instability.
- Trial name
- NCT04587193
- Testing
- Robotic-assist gait training device
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
PreTerm Birth
Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth
More than 1.5 million HIV-infected women become pregnant each year. Approximately half have access to antiretroviral therapy (ART), but all are at increased risk of preterm birth (PTB).
- Trial name
- VP (NCT02970552)
- Testing
- Vaginal Progesterone
- Where
- Zambia
- Volunteers
- 140 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-retroviral therapy (ART) activity of monotherapy with MK-8504 (a tenofovir pro-drug), in ART-naïve Human Immunodeficiency Virus (HIV)-1…
- Trial name
- NCT03188523
- Testing
- MK-8504
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Harm Reduction, HIV Infections
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.
- Conditions
- Harm Reduction, HIV Infections, Drug Use
- Trial name
- NCT04650269
- Testing
- Biktarvy 50Mg-200Mg-25Mg Tablet, HIV care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Miami
Risk Behavior, Medication Adherence
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
This study will test whether 3H+ (Holistic Health for HIV) is comparable to the original HHRP+ (Holistic Health Recovery Program) in reducing HIV risk behaviors and improving ART (Antiretroviral Therapy) adherence in a randomized…
- Conditions
- Risk Behavior, Medication Adherence, HIV
- Trial name
- NCT01741311
- Testing
- 3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Connecticut
HIV Infections, Cytomegalovirus
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral…
- Conditions
- HIV Infections, Cytomegalovirus, CMV
- Trial name
- ELICIT (NCT04840199)
- Testing
- Letermovir Oral Tablet
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV
This is an unblinded cluster-randomized study to evaluate the effectiveness of two strategies for scripting/dispensing of antiretroviral therapy (ART) on retention, virologic suppression, and cost compared to the standard of…
- Trial name
- INTERVAL (NCT03101592)
- Testing
- Three-month ART dispensing, Six-month ART dispensing
- Where
- 2 sites in Malawi, Zambia
- Volunteers
- 9,118 people
- Sponsor
- University of California, Los Angeles
Infertility
FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled ovarian hyperstimulation in a GnRH-antagonist…
- Trial name
- FAST (NCT01969201)
- Testing
- Urofollitrophin, Follitrophin alpha
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 710 people
- Sponsor
- IBSA Institut Biochimique SA
Cancer
Creative Arts Therapy (CAT) in the Center for Cancer and Blood Disorders
The purpose of the study is to evaluate the effectiveness of Creative Arts Therapy (CAT) on pediatric patients undergoing chemotherapy in the Infusion Center at Children's Hospital Colorado Center for Cancer and Blood Disorders.
- Trial name
- NCT04208243
- Testing
- Creative Arts Therapy
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Colorado, Denver
Alzheimer Disease, Early Onset
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and…
- Trial name
- ART-AD (NCT04552795)
- Testing
- 3TC
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
HIV/AIDS
VITAL Start: Brief Facility-based Video Intervention
This a multi-center, parallel group, randomized controlled outcome assessor blinded trial with a qualitative descriptive component that seeks to assess the effectiveness of a brief facility-based video intervention to optimize…
- Trial name
- VITAL (NCT03654898)
- Testing
- VITAL Start: Video-based pre-ART counseling, Standard of Care
- Where
- Malawi
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine